Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | TYK2 | P29597 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | CYP26A1 | O43174 | 4/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.35 |
| ▸ | PARP1 | P09874 | 2/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | KIF11 | P52732 | 2/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6788457 | 0.92 | HCAR2 (0.39) | CYP26A1CYP19A1 | |
| SCHEMBL6787520 | 0.82 | JAK2 (0.37) | JAK2JAK1TYK2JAK3CHEK1 | |
| SCHEMBL6786978 | 0.82 | ALDH1A1 (0.41) | JAK2JAK1TYK2JAK3CYP19A1 | |
| SCHEMBL6800372 | 0.74 | HCAR2 (0.43) | CHEK1 | |
| SCHEMBL6793773 | 0.73 | HCAR2 (0.48) | CYP19A1 | |
| SCHEMBL6793173 | 0.62 | MEN1 (0.43) | ESR1ESR2CHEK1 | |
| SCHEMBL8466193 | 0.59 | CYP19A1 (0.60) | CYP26A1CYP19A1 | |
| SCHEMBL13827495 | 0.59 | NR0B1 (0.44) | CYP26A1KIF11 | |
| SCHEMBL8466044 | 0.59 | CYP19A1 (0.50) | CYP26A1CYP19A1KIF11 | |
| SCHEMBL15969586 | 0.59 | CYP19A1 (0.67) | CYP26A1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | MKNK2, MAPKAPK2, MAP3K2 | JAK2 394/4885JAK1 405/4885TYK2 537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.